Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 383 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
383 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.
ClinicalTrials.gov ID: NCT03412877
TrialFetch AI summary: This trial enrolls adults with unresectable, recurrent, or metastatic solid tumors (including dedicated cohorts for melanoma post anti-PD-1 therapy and platinum-resistant ovarian cancer) to receive DF6215—a novel, half-life extended monovalent IL-2 agonist designed to selectively activate CD8+ T cells and NK cells—either alone or in combination with pembrolizumab. Participants must have ECOG 0-1, adequate organ function, and meet strict cardiac and infection criteria.
ClinicalTrials.gov ID: NCT06108479
TrialFetch AI summary: Eligible patients are adults with locally advanced or metastatic NSCLC harboring EGFR ex19del or L858R mutations who have developed C797X-mediated resistance after prior third-generation EGFR TKI (e.g., osimertinib) therapy; participants receive STX-241, an oral, CNS-penetrant, fourth-generation EGFR inhibitor specifically designed to overcome C797X resistance.
ClinicalTrials.gov ID: NCT06567015
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
TrialFetch AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12D and HLA-C*08:02 (e.g., NSCLC, colorectal, pancreatic, endometrial) after ≥1 prior therapy receive lymphodepletion followed by a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D and CRISPR-edited to disrupt TGF-βRII, with IL-2 support. Single-arm dose escalation assessing safety and preliminary efficacy.
ClinicalTrials.gov ID: NCT06218914
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic colorectal, pancreatic, gastric/gastroesophageal junction, or lung cancers that have progressed after standard therapy, testing PF-08046050 (SGN-CEACAM5C), an anti-CEACAM5 antibody-drug conjugate linked to a topoisomerase I inhibitor, as monotherapy and in combination with bevacizumab. Eligible patients must have measurable disease and ECOG 0-1.
ClinicalTrials.gov ID: NCT06131840
TrialFetch AI summary: Eligible patients are adults with advanced, folate receptor alpha–expressing solid tumors—including ovarian, endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, or colorectal cancer—without uncontrolled CNS metastases or significant comorbidities. Treatment involves investigational LY4170156, a topoisomerase I inhibitor antibody-drug conjugate targeting FRα, given as monotherapy or combined with bevacizumab or carboplatin.
ClinicalTrials.gov ID: NCT06400472
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741
TrialFetch AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194